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Abstract
Carcinoma in situ (CIS) is the noninvasive precursor of
most human testicular germ cell tumors. In normal
seminiferous epithelium, specialized tight junctions
between Sertoli cells constitute the major component
of the blood–testis barrier. Sertoli cells associated
with CIS exhibit impaired maturation status, but their
functional significance remains unknown. The aim was
to determine whether the blood–testis barrier is mor-
phologically and/or functionally altered. We investi-
gated the expression and distribution pattern of the
tight junction proteins zonula occludens (ZO) 1 and 2 in
normal seminiferous tubules compared to tubules
showingCIS. Innormal tubules, ZO-1andZO-2 immuno-
staining was observed at the blood–testis barrier
region of adjacent Sertoli cells. Within CIS tubules,
ZO-1 and ZO-2 immunoreactivity was reduced at the
blood–testis barrier region, but spread to stain the
Sertoli cell cytoplasm. Western blot analysis confirmed
ZO-1 and ZO-2, and their respective mRNA were shown
by RT-PCR. Additionally, we assessed the functional
integrity of the blood–testis barrier by lanthanum
tracer study. Lanthanum permeated tight junctions in
CIS tubules, indicating disruption of the blood–testis
barrier. In conclusion, Sertoli cells associated with CIS
show an altered distribution of ZO-1 and ZO-2 and lose
their blood–testis barrier function.
Neoplasia (2006) 8, 1019–1027
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Introduction
Normal spermatogenesis (NSP) depends on functional
interactions between somatic Sertoli cells and reproductive
germ cells. During puberty, Sertoli cells undergo terminal
differentiation, including cessation of cell division, loss of
expression of maturation markers, and formation of the
blood–testis barrier [1–3]. The blood–testis barrier divides
the seminiferous epithelium into a basal compartment and
an adluminal compartment. The basal compartment con-
tains spermatogonia and preleptotene spermatocytes, which
still have access to circulating blood-borne substances [1,4].
The adluminal compartment contains all other germ cells and is
a structurally defined environment created by the secretory
and endocytic activities of Sertoli cells. This immune-free en-
vironment protects postmeiotic germ cells and is essential
for spermatogenesis [5].
The blood–testis barrier is composed of tight junctions,
adherens junctions, and gap junctions. Tight junctions consti-
tute the major structural component of this Sertoli cell junctional
complex [1,4]. In general, tight junctions are regions where
plasma membranes of adjacent cells form a series of contacts
that appear to completely occlude the extracellular space,
thereby creating an intercellular barrier and intramembrane
diffusion fence [6,7]. The tight junction structure (Figure 1)
can be separated basically into two regions of molecules: (1)
the transmembrane region, which includes those molecules
that mechanically confer adhesiveness to cells by bonding to
the same molecule on adjacent cells [8] (these proteins consist
of occludin [9], the claudin multigene family [10], and junc-
tional adhesionmolecules [11]); and (2) the plaque or peripheral
region of the tight junction, which comprises those molecules
that anchor transmembrane proteins to the tight junction struc-
ture and link them to the cell cytoskeleton and signalling
pathways, essentially controlling tight junction structure and
function [12–14]. This category comprehends the zonula occlu-
dens (ZO) family of MAGUK proteins, consisting of ZO-1 [15],
ZO-2 [16], and ZO-3 [17]. Concerning the tight junction proteins
of the human blood–testis barrier, only ZO-1 has been posi-
tively identified to date [18].
The 220-kDa protein ZO-1 is likely to constitute the major
backbone of the tight junction plaque [19]. ZO-1 is directly linked
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to actin filaments, anchoring tight junction transmembrane
proteins to the actin cytoskeleton [20,21]. Chung et al. [22]
demonstrated a significant increase in rat Sertoli cell ZO-1
expression preceding the establishment of tight junctions
in vitro. ZO-1 binds directly to occludin [23], claudins
[24,25], and junctional adhesionmolecules [26]. ZO-1 binding
to occludin has been shown to be important in targeting
occludin to tight junctions and in anchoring occludin at the
extracellular seal [23,27]. Additionally, ZO-1 binds various
gap junction proteins, including connexin 43 (Cx43) [28,29],
the predominant Cx in Sertoli cells [30]. InmouseSertoli cells,
the colocalization of ZO-1, occludin, and Cx43 to the same
junctional complexes was described by Cyr et al. [31], who
suggested that cell–cell structural adhesion and communi-
cation occur at the same cell–cell interfaces and that ZO-1
may regulate the intracellular assembly of both of these
junctions. Direct binding of ZO-2 to Cx43 has been recently
reported in cultured normal rat kidney epithelial cells [32].
Testicular carcinoma in situ (CIS) is a noninvasive precur-
sor of testicular germ cell tumors [33], which are the most
common type of cancer in young men, exhibiting a rising
incidence [34,35]. Testicular cancer progression has been
correlated with an impaired status of Sertoli cell differentia-
tion [36–39], which includes downregulation of Cx43 [40].
Functional significance behind the impaired maturation status
of Sertoli cells associated with CIS cells remains unknown.
Thus, the aim of the present study was to determine whether
the blood–testis barrier is morphologically and/or functionally
altered. Considering the colocalization of tight junctions
and gap junctions at the blood–testis barrier and considering
that ZO-1 and ZO-2 are associated with both, we investi-
gated the expression and distribution pattern of these pro-
teins in human seminiferous tubules with NSP compared to
tubules showing CIS. Additionally, the functional integrity of
the blood–testis barrier in CIS tubules was examined by as-




Testicular biopsies, which were taken for diagnostic pur-
poses, were immersed in Bouin’s fixative for 24 hours and
embedded in paraffin wax using standard techniques. Sec-
tions (5 mm) were stained with hematoxylin and eosin and
scored for spermatogenesis. Diagnosis of CISwas confirmed
by immunohistochemistry, using a monoclonal antibody to
placental alkaline phosphatase, according to the manu-
facturer’s protocol (DAKO, Hamburg, Germany).
After written informed consent had been obtained, immu-
nohistochemistry for ZO-1 and ZO-2 was performed on
biopsies from 9 testes of 8 patients (ages 28–47 years;
mean = 38.5 years) with NSP (by histology; score 10–9)
[41] and from 23 testes of 19 patients (ages 20–47 years;
median = 33.9 years) with seminiferous tubules infiltratedwith
Figure 1. Schematic drawing of the current model of the tight junction structure in the seminiferous epithelium. Tight junctions are formed between adjacent Sertoli
cells near the basal lamina, constituting the blood– testis barrier and separating the seminiferous epithelium into a basal compartment and an adluminal
compartment. SG, spermatogonium; pSP, preleptotene/leptotene spermatocyte; SP, pachytene spermatocyte; rSp, round spermatid; Sp, elongated spermatid;
SC, Sertoli cells; JAM, junctional adhesion molecules (modified from Lui et al. [14]).
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CIS and impaired spermatogenesis (score 7–0) (Table 1).
Deparaffinized and rehydrated sections for ZO-1 and ZO-2
immunostaining were microwave-treated at 1000 W in so-
dium citrate buffer (pH 6.0) for 15 to 20 minutes. Sections
were blocked with 3% H2O2 in methanol for 30 minutes at
room temperature (RT), with 3% slim milk powder (Heirler
Cenouis, Radolfzell, Germany) in Tris–HCl buffer for 30 min-
utes at RT, and, finally, with 5% bovine serum albumin (BSA)
in Tris–HCl buffer for 30 minutes at RT. Afterward, they
were incubated overnight with rabbit polyclonal anti–ZO-1
(1:500; Zymed, San Francisco, CA) or goat polyclonal anti–
ZO-2 (1:300; Santa Cruz Biotechnology, Santa Cruz, CA)
primary antibody in a humid chamber at 4jC. Sections were
then exposed for 45 minutes at RT to biotinylated secondary
antibody, goat anti-rabbit IgG for ZO-1 (1:100; DAKO), and
rabbit anti-goat IgG for ZO-2 (1:100; DAKO). Then, sections
were treated with a Vectastain Elite ABC Kit (Vector, Burlin-
game, CA) for 45 minutes at RT. Immunoreaction was visu-
alized using DAB solution (Biologo, Kronshagen, Germany)
for 1 to 2 minutes at RT. Following each incubation, sections
were washed thoroughly with 0.1 M Tris–HCl buffer, pH 7.4.
Slices were counterstained with hematoxylin for 10 seconds
and rinsedwith runningwater. Finally, sectionsweremounted
with Kaiser’s glycerol gelatin (Merck, Darmstadt, Germany).
Control sections were treated with normal appropriate animal
sera or phosphate-buffered saline (PBS), omitting the pri-
mary antibody, and were negative throughout. For positive
control, mouse testes were used. Experiments were re-
peated thrice.
Protein Extraction and Western Blot Analysis
For Western blot analysis, testicular biopsies of 14 men
(ages 35–64 years; mean = 42.9 years) were snap-frozen in
liquid nitrogen and stored at 80jC until further processing.
Histologic evaluation of these testes revealed NSP in eight
cases and CIS with residual spermatogenesis (RSP) in six
cases (Table 1). Protein extraction was carried out using the
TRIzol reagent as recommended by the manufacturer (Life
Technologies, Karlsruhe, Germany). The same amount of
protein was loaded per lane. Proteins for ZO-1 were frac-
tionated on 3–8% Tris–Acetat gel (Invitrogen, Karlsruhe,
Germany) under reducing conditions, using 1 Tris–Acetat
SDS Running Buffer (Invitrogen) and the protein marker Dual
Color Precision Plus Protein Standards (Bio-Rad, Mu¨nchen,
Germany). Proteins for ZO-2 were fractionated on 4% to 12%
Tris–Bis Gel (Invitrogen) under reducing conditions, using
1NuPAGEMOPS-SDSRunning Buffer (Invitrogen) and the
protein marker See Blue Plus 2 (Invitrogen). Then, proteins
were blotted (at 30 V for 1 hour; Biometra Standard Power
Pack P25; Biometra, Go¨ttingen, Germany) onto a nitro-
cellulose membrane (Invitrogen), using 1 NuPAGE Mops-
SDS Transfer Buffer (Invitrogen). The membrane was
blocked with 5% BSA and 5% nonfat dry milk in 0.1 M PBS
(pH 7.4) for 30 minutes at RTand incubated with anti–ZO-1
rabbit polyclonal antibody (1:500; Zymed) or anti–ZO-2 goat
polyclonal antibody (1:500; Santa Cruz Biotechnology) in
PBS with 1% BSA and 0.1% Tween 20 (Sigma-Aldrich,
Munich, Germany) overnight at RT. After blocking with 5%
goat serum in PBS for ZO-1 or with 5% rabbit serum in PBS
for ZO-2 for 30minutes at RT, biotinylated goat anti-rabbit IgG
for ZO-1 (1:1000; DAKO) or biotinylated rabbit anti-goat
IgG for ZO-2 (1:1000; DAKO) in PBS with 1% BSA and





NSP CIS + RSP CIS Only Score
1 39 x 10
2 39 x 10
3 39 x 10
4 28 x 10
5 39 x 10
6 47 x 9
7 38 x 10
8 44 x 10
9 34 x 10
10 47 x 5
11 32 x 7
12 32 x 5
13 29 x 4
14 29 x 5
15 37 x 6
16 27 x 4
17 41 x 5
18 40 x 3
19 41 x 6
20 37 x 0
21 37 x 0
22 31 x 0
23 26 x 0
24 26 x 0
25 35 x 0
26 20 x 0
27 36 x 0
28 29 x 0
29 31 x 0
30 42 x 0
31 35 x 0
32 29 x 0
33 49 x 10
34 35 x 10
35 52 x 10
36 37 x 10
37 64 x 10
38 40 x 10
39 38 x 9
40 44 x 10
41 39 x 3
42 38 x 4
43 41 x 5
44 47 x 5
45 42 x 3
46 35 x 4
47 35 x 10
48 37 x 10
49 37 x 5
50 36 x 6
51 43 x 4
52 30 x 6
53 47 x 3
54 34 x 5
55 40 x 7
56 38 x 0
57 37 x 0
58 43 x 0
59 46 x 0
60 35 x 0
61 49 x 0
NSP, normal spermatogenesis; RSP, residual spermatogenesis; CIS, carci-
noma in situ.
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0.1% Tween 20 was used as secondary antibody (60 min-
utes, RT). Finally, the membrane was treated with Vectastain
Elite ABC Kit (Vector) and developed with True Blue Perox-
idase Substrate (KPL, Gaithersburg, MD). Control Western
blot analyses were carried out by omitting the primary anti-
body and by using normal appropriate animal sera. For posi-
tive control, mouse and canine testes were used. Western
blot experiments were repeated thrice.
RNA Extraction, DNase Treatment, cDNA Synthesis,
and Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) from Tissue Homogenates
For RT-PCR, the same biopsies were used as forWestern
blot analysis. RNAwas extracted with TRIzol reagent accord-
ing to the manufacturer’s protocol (Life Technologies) and
then incubated with RNase-free DNase I (1–3 U/mg RNA;
Roche, Mannheim, Germany) for 40 minutes at 37jC. First-
strand cDNA synthesis was performed using Superscript II
Reverse Transcriptase, according to the manufacturer’s pro-
tocol (Gibco BRL, Eggenstein, Germany). Resulting cDNA
sequences were forwarded to PCR. PCR master mix
contained 31.75 ml of diethylpyrocarbonate (DEPC)–water,
10 ml of 5PCR buffer (Promega, Heidelberg, Germany), 4 ml
of 25 mM MgCl2, 1 ml of 10 mM dNTP (Promega), 1 ml of
forward primer (10 pmol), 1 ml of reverse primer (10 pmol), 1 ml
of cDNA, and 0.25 ml of Go-Taq-Flexi DNA Polymerase
(Promega). Primers (Table 2) were purchased from MWG-
Biotech (Ebersberg, Germany). Probes were run on a
thermocycler (T3; Biometra) under the following conditions:
1, 95jC, 2 minutes; 29 [95jC, 30 seconds; 55jC, 30 sec-
onds; 72jC, 30 seconds]; 72jC, 7 minutes, resulting in a
product of 370 bp for ZO-1; 1, 95jC, 2 minutes; 34 [95jC,
30 seconds; 54jC, 30 seconds; 72jC, 30 seconds]; 72jC,
7min, resulting in a product of 306 bp for ZO-2 F1 and 476 bp
for ZO-2 F2 (data not shown). Amplicons were separated on
a 2% agarose gel and visualized with SYBR-Green (Sigma-
Aldrich). All experiments included controls lacking reverse
transcriptase enzyme to exclude contamination with genomic
DNA or were run with DEPC water instead of RNA to exclude
contamination from buffers and tubes. Both controls were
negative. Sequencing of PCR products was performed by
Qiagen Sequencing Service (Qiagen, Hilden, Germany).
Lanthanum Nitrate Tracer Study
Biopsies from 15 testes of 15 men (ages 30–49 years;
mean = 39.1 years) attending the University Hospital
Hamburg-Eppendorf were obtained for diagnostic purposes
(Table 1). After written informed consent had been obtained,
tissue samples were cut into two blocks. One block was
immediately fixed by immersion in 5.5% glutaraldehyde in
0.05 M cacodylate buffer adjusted to pH 7.35 (at least
3 hours), postfixed in 1% OsO4 (1 hour), dehydrated, and
embedded in Epon 812 (Serva, Heidelberg, Germany). The
second block was processed identically, but fixation solution
contained 1% lanthanum nitrate. Semithin sections were
stained with toluidine blue, mounted in Eukitt (Riedel-de
Haen, Seelze, Germany), and photographed. Thin sections
were double-stained with uranyl acetate and lead citrate, and
examined in Zeiss EM 109 (Zeiss, Oberkochen, Germany).
Histologically, the material was divided into two groups: (1)
tubules with NSP (2 testes), and (2) tubules with CIS cells,
which are large atypical-appearing germ cells showing char-
acteristic ultrastructural features such as irregular nuclei
containing numerous nucleoli and large amounts of glycogen
granula [42] (13 testes).
Results
Immunohistochemistry, Western Blot Analysis,
and RT-PCR
In sections with NSP, ZO-1 (data not shown) and ZO-2
immunostaining was concentrated and precisely colocalized
in a linear fashion at the basolateral site of adjacent Sertoli
cells, as shown in Figure 2A. Immunoreactive ZO-1 and ZO-2
formed an almost continuous belt at the base of normal
seminiferous epithelium. In tubules with CIS cells and RSP,
there was progressive loss of ZO-1 and ZO-2 immuno-
staining from its normal intercellular location at the baso-
lateral site of Sertoli cells, becoming more diffuse and
decreasing in intensity (Figure 2B). In tubules that are devoid
of normal germ cells in the presence of CIS cells (CIS-only
tubules), additional immunoreaction was observed at the
lateral site of Sertoli cells up to the adluminal compartment,
as well as in their cytoplasm (Figure 2C).
Western blot analysis (Figure 3) revealed ZO-1 immuno-
reactivity by a triple band between 220 and 240 kDa in testes
with NSP and by a weaker triple band at the same level in
testes with CIS. ZO-2 immunoreactivity was revealed by a
band at approximately 160 kDa in testes with NSP and by a
weaker band at the same level in testes with CIS.
Using RT-PCR (Figure 4), mRNA encoding ZO-1 and ZO-2
were identified in testes with NSP and CIS, detecting specific
bands of 370-bp and 306-bp PCR products, respectively.
Sequencing of PCR products confirmed the identity of human
tight junction proteins ZO-1 and ZO-2mRNA (NCBI accession
no. L14837 for ZO-1 and accession no. NM_201629 for ZO-2].
Lanthanum Nitrate Tracer Study
Lanthanum nitrate penetrated the basal lamina to enter
seminiferous tubules and subsequently crossed into the inter-
cellular spaces of the seminiferous epithelium. Within the
normal seminiferous epithelium, lanthanum was spread
evenly between Sertoli cells and early stages of spermato-
genesis, but was unable to pass Sertoli cell junctions. Only
spermatogonia types A and B were surrounded by the
Table 2. RT-PCR Primer Pairs for Analysis of ZO Molecules.
Molecule Primer Sequence
ZO-1 ZO-1F 5V-CGG TCC TCT GAG CCT GTA AG-3V
ZO-1R 5V-GGA TCT ACA TGC GAC GAC AA-3V
ZO-2 ZO-2R 5V-AAC TTC TGC CAT CAA ACT CG-3V
ZO-2F1 5V-CCG GAG GCA GAG ACA ACC C-3V
ZO-2F2 5V-CGC CTA CGC GGG ACC TGT G-3V
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electron-opaque tracer (Figure 5). In tubules containing only
CIS cells, lanthanum passed inter-Sertoli cell junction units,
identified by typical subsurface bundles of actin filaments and
associated endoplasmic reticulum. The tracer was detectable
in the adluminal compartment up to the lumen (Figure 6). In
tubules with CIS cells and RSP, it could be determined
whether germ cells (such as early round spermatids) are
impregnated by the tracer, indicating local disruption of the
blood–testis barrier (Figure 7).
Discussion
Sertoli cells associated with CIS cells undergo a process of
dedifferentiation, as seen, for example, by the reexpression
of cytokeratin 18 intermediate filaments [37]. Cytokeratin 18
intermediate filaments are usually observed in Sertoli cells of
fetal testes and indicate a state of undifferentiation [43–45].
Furthermore, Brehm et al. [40] reported the disappearance
of Cx43 from Sertoli cells in tubules infiltrated with CIS,
which is typically expressed together with terminal differenti-
ation of Sertoli cells during puberty [30]. To determine the
functional significance of this impaired maturation status of
Figure 3. Western blot analysis for ZO-1 and ZO-2 of testis homogenates. Western blot analysis revealed ZO-1 immunoreactivity by a triple band between
approximately 220 and 240 kDa in testes with NSP and by a weaker triple band at the same level in testes with CIS. ZO-2 immunoreactivity was revealed by a band
at approximately 160 kDa in testes with NSP and by a weaker band at the same level in testes with CIS.
Figure 4. RT-PCR analysis for ZO-1 and ZO-2 mRNA of testis homogenates.
By RT-PCR, an amplification product of expected size (370 bp for ZO-1 and
306 bp for ZO-2) is obtained in testes with NSP and in testes showing CIS,
confirming the presence of ZO-1 and ZO-2 mRNA.
Figure 2. Immunohistochemical localization of ZO-2 in human seminiferous
epithelium. (A) Cross section of a normal seminiferous tubule. Immuno-
reactive ZO-2 is localized between Sertoli cells at the basal compartment,
consistent with the site of the blood– testis barrier (arrows). (B) Cross section
of a tubule with CIS cells and RSP. In regions with RSP, ZO-2
immunostaining is concentrated at the basolateral region of Sertoli cells
(arrows), whereas in regions containing CIS cells, ZO-2 immunostaining
became weak and diffuse (arrowheads). (C) Cross section of a seminiferous
tubule containing CIS cells, and cross section of a part of a normal tubule.
Within the CIS-only tubule, ZO-2 immunostaining became even weaker and
more diffuse around the basolateral site, but spread to stain the lateral site of
Sertoli cells up to the adluminal compartment, as well as their cytoplasm
(arrows). Bar = 50 m.
ZO and Blood–Testis Barrier in Testicular CIS Fink et al. 1023
Neoplasia . Vol. 8, No. 12, 2006
Sertoli cells, we examined the expression and distribution
pattern of the tight junction proteins ZO-1 and ZO-2, as well
as the permeability of the blood–testis barrier in tubules
containing CIS cells.
Using immunohistochemistry, Western blot analysis, and
RT-PCR, we could demonstrate ZO-1 and ZO-2 in the semi-
niferous epithelium with NSP, as well as with CIS. In normal
seminiferous epithelium, ZO-1 and ZO-2 formed continuous
belts of strong immunohistochemical staining at the level of
the blood–testis barrier. This distribution coincided with the
expression of ZO-1 reported in the testes ofmice [46], rats [4],
guinea pigs [47], and dogs [48], as well as in human testes
[18]. The expression of ZO-2 in inter-Sertoli tight junctions
has only been described so far in canine testes [49].
Within CIS tubules, ZO-1 and ZO-2 immunoreactivity
became weak and diffuse at the blood–testis barrier region
but spread to stain the entire lateral site of Sertoli cells, as well
as their cytoplasm, indicating altered localization. Similar
findings have been reported in breast tissues, where ZO-1
and ZO-2 staining was confined to intercellular regions in
normal tissues whereas staining was diffuse and cytosolic
in tumor tissues [50]. Glaunsinger et al. [51] have shown that
ZO-2 is a cellular target for tumorigenic Ad9 E4-ORF1 and
that this interaction results in aberrant sequestration of
ZO-2 within the cytoplasm.
Permeability of tight junctions is best assessed using
lanthanum nitrate as an electron-opaque tracer given that
the number of strands of tight junctions is not a reliable
indicator of junctional tightness [52]. As reported in previous
studies [1,53–56], lanthanum entered the basal lamina of
Figure 6. Electron micrograph of a seminiferous tubule containing CIS cells.
Lanthanum tracer (arrow) surrounds CIS cells on the basal lamina. Bar =
10 m. Enlargement of inset: Inter-Sertoli cell junctional complex, typified by
subsurface bundles of actin filaments and associated cisternae of endoplasmic
reticulum. Lanthanum tracer (arrows) passes through the junctional complex,
illustrating that tight junctions were functionally disrupted. Bar = 0.5 m.
Figure 7. Electron micrograph of a seminiferous tubule containing CIS cells
and RSP. Lanthanum tracer (black arrow) surrounds the CIS cell on the basal
lamina and the neighboring round spermatid (inset a), illustrating local
disruption of the blood– testis barrier. In the area of residual spermato-
genesis, the intercellular space of a round spermatid is free of lanthanum
(inset b), indicating an intact blood– testis barrier. Bar = 10 m. Enlargement
of inset a: Round spermatid with lanthanum in the intercellular space (black
arrow). Bar = 1 m. Enlargement of inset b: Round spermatid without
lanthanum in the intercellular space (transparent arrow). Black arrow shows
lanthanum in the intercellular space of two Sertoli cells. Bar = 1 m.
Figure 5. Electron micrograph of a seminiferous tubule showing NSP.
Lanthanum tracer, which appears as an electron-dense material (arrow),
impregnates spermatogonia on the basal lamina. Bar = 5 m. Enlargement of
inset: Inter-Sertoli cell junctional complex, where tracer (arrow) penetration is
stopped by tight junctions. Bar = 0.5 m.
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seminiferous tubules and subsequently penetrated the inter-
cellular spaces of adjacent Sertoli cells and spermatogonia.
In tubules with NSP, the tracer was consistently stopped at
Sertoli cell junctions of the basal compartment and there-
fore excluded from the adluminal compartment. In contrast,
in sections with CIS, lanthanum passed through tight junc-
tion leaflets and entered the adluminal compartment, indi-
cating disruption of the blood–testis barrier. Thus, in the
present study, it was demonstrated for the first time that
Sertoli cells associated with CIS cells lose their blood–testis
barrier function.
The loss of the functional integrity of the blood–testis
barrier in CIS tubules reflected by the penetration of lantha-
numwas consistent with changes in the distribution pattern of
ZO-1 and ZO-2. Thus, the dislocation of ZO-1 and ZO-2 from
the basolateral region of Sertoli cells may be related to the
increased permeability of the blood–testis barrier in CIS
tubules. Changes in the distribution pattern of ZO-1 have
been related to an increased permeability of tight junctions
by a number of previous studies. In MDCK cells, for in-
stance, hepatocyte growth factor caused the redistribution
of ZO-1, reducing its association with occludin and moving
it away from the site of tight junctions to the cytoplasm,
which in turn perturbed the tight junction–permeability barrier
[57]. Toxicants such as lindane and CdCl2, which induce
disruption of the blood–testis barrier, also delocalize ZO-1
from Sertoli cell membranes to the cytoplasmic compartment
[58,59]. Yan and Cheng [60] reported that occludin and ZO-1
appeared to diffuse away from the blood–testis barrier site
during Adjudin-induced germ cell depletion. Furthermore,
an ATP depletion–repletion model suggested that ZO-1
becomes associated with the cytoskeletal protein fodrin when
ATP is depleted from the system. This, in turn, pulls ZO-1
laterally away from sites of tight junctions, inducing tight
junction leakiness. On repletion of ATP, the association
between ZO-1 and fodrin becomes disrupted, allowing
ZO-1 molecules to move back to tight junction sites, reseal-
ing tight junctions [61].
Tight junctions are disrupted in a number of tumor types,
including stomach, colon, and breast cancers, and are asso-
ciated with downregulation of ZO-1 and occludin [62,63].
Yoshida et al. [64] noted strong staining for ZO-1 on cell–cell
contact in well differentiated and moderately differentiated
human gastric adenocarcinoma cell lines. In contrast, poorly
differentiated adenocarcinoma cells showed a markedly
lower ZO-1 staining on cell–cell contact, whereas ZO-1
immunostaining in the cytosol was more abundant. The
authors suggest that the localization of ZO-1 on cell–cell
contact varies depending on the degree of differentiation of
gastric cancer cells.
Changes in the distribution pattern of ZO-1 and ZO-2 and
the disruption of the blood–testis barrier are first detectable
in tubules containing CIS cells associated with germ cells
at the level of primary spermatocytes or even single early
round spermatids and are progressive with increasing
numbers of CIS cells. These data are in line with pre-
vious studies showing that Sertoli cells associated with CIS
undergo a process of dedifferentiation indicated by the
progressive reexpression of cytokeratin 18 intermediate fila-
ments [37] and loss of Cx43 expression [40,65].
We foundZO-1 and ZO-2 to be associatedwith the blood–
testis barrier region in men with NSP. In the case of ZO-2, this
is the first report to show the localization of this tight junction
protein in human seminiferous epithelium. The ZO-1 and
ZO-2 expression pattern was also demonstrated at different
stages of human testicular CIS.Within CIS tubules, ZO-1 and
ZO-2 immunoreactivity became weak, diffuse, and cytosolic.
Furthermore, we demonstrated the loss of functional integrity
of Sertoli cell tight junctions in CIS tubules. The disruption of
the blood–testis barrier may be related to the dislocation
of ZO-1 and ZO-2 to the Sertoli cell cytoplasm. It can be
concluded that the impaired maturation status of Sertoli cells
associated with CIS cells includes alterations in the distribu-
tion of ZO-1 and ZO-2 and the breakdown of the blood–testis
barrier. The distribution pattern and impact of the trans-
membrane tight junctional proteins occludin and claudins
have to be determined.
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